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Abstract
Bisphosphonates are the most prescribed preventative treatment for osteoporosis. However, their
long-term use has recently been associated with atypical fractures of cortical bone in patients who
present with low-energy induced breaks of unclear pathophysiology. The effects of
bisphosphonates on the mechanical properties of cortical bone have been exclusively studied
under simple, monotonic, quasi-static loading. This study examined the cyclic fatigue properties of
bisphosphonate-treated cortical bone at a level in which tissue damage initiates and is accumulated
prior to frank fracture in low-energy situations. Physiologically relevant, dynamic, 4-point
bending applied to beams (1.5 mm × 0.5 mm × 10 mm) machined from dog rib (n=12/group)
demonstrated mechanical failure and micro-architectural features that were dependent on drug
dose (3 groups: 0, 0.2, 1.0 mg/kg/day; Alendronate [ALN] for 3 years) with cortical bone tissue
elastic modulus (initial cycles of loading) reduced by 21% (p<0.001) and fatigue life (number of
cycles to failure) reduced in a stress-life approach by greater than 3-fold with ALN1.0 (p<0.05).
While not affecting the number of osteons, ALN treatment reduced other features associated with
bone remodeling, such as the size of osteons (−14%, ALN1.0: 10.5±1.8, VEH: 12.2±1.6, ×103
µm2; p<0.01) and the density of osteocyte lacunae (−20%; ALN1.0: 11.4±3.3, VEH: 14.3±3.6,
×102 #/mm2; p<0.05). Furthermore, the osteocyte lacunar density was directly proportional to
initial elastic modulus when the groups were pooled (R=0.54, p<0.01). These findings suggest that
the structural components normally contributing to healthy cortical bone tissue are altered by high-
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dose ALN treatment and contribute to reduced mechanical properties under cyclic loading
conditions.
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bone remodeling; osteocytes; atypical fracture; antiresorptives; osteoporosis
1 Introduction
Bisphosphonates, including oral alendronate developed by Merck (Fosamax) and now
available in generic form, are bone anti-resorptive drugs. As the most commonly prescribed
treatment for the prevention of osteoporotic fracture, over 5 million U.S. patients filled a
prescription for an oral bisphosphonate in each year from 2005 to 2009, the last year in
which reliable data are available.[1] By suppressing resorption, bisphosphonates slow the
loss of bone mass at the hip and spine.[2] Consequently, fracture risk at these highly
trabecular skeletal sites is reduced.[3–7] However, long-term suppression of bone resorption
and remodeling also affects the quality of bone by altering tissue-level micro-architecture
and composition.[8–10] Notably, in iliac crest patient biopsies, bisphosphonate treatment
was shown to slow the loss of trabecular micro-architecture, quantified as number, thickness
and interconnectedness of plate-like and rod-like elements.[2, 11] In these same biopsies,
[12] and in dogs (vertebrae and tibia) treated with anti-resorptives,[13, 14] cortical bone
micro-architecture and composition have demonstrated more tissue damage and mineral
crystal homogeneity, two components of bone’s mechanical quality.
Alterations in quality can also impact cortical bone’s fracture resistance. Indeed, several
studies on the mechanical behavior of short-term (1 year) and long-term (3 years)
bisphosphonate-treated bones (ilium, ribs, spinous processes and vertebrae) from dogs, a
species exhibiting intra-cortical resorption patterns similar to human, have shown increased
stiffness, or initial resistance to a mechanical load, yet decreased toughness, or energy
absorption to fracture, as estimated from whole-bone mechanical testing.[8, 13, 15–18]
More direct tests at the tissue level on machined specimens from tibia of bisphosphonate-
treated animals and iliac crest biopsies from treated patients have also suggested lower
toughness by traditional bone beam bending,[19] and “plastic deformation resistance” by
nanoindentation (a non-traditional surrogate),[20] which are both generally associated with
increased brittleness.
While remodeling suppression with bisphosphonates is associated with changes in material
properties determined from these quasi-static mechanical tests in which failure occurs in a
single loading cycle, properties of the tissue under more realistic, cyclic (fatigue) loading
conditions are unknown. In vivo, bones are naturally loaded cyclically. This repetitive
loading results in initiation of micro-damage that is normally repaired by targeted
remodeling, the process of bone tissue renewal.[21, 22] Bone tissue aging is associated with
brittleness,[13, 17] and one plausible explanation for the recently described association of
atypical cortical shaft fractures occurring after long-term (>3–5 years) bisphosphonate
treatment[1, 23–30] is that by slowing targeted bone tissue repair, micro-damage
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accumulates, eventually resulting in a frank fracture. While the mechanisms have not been
elucidated, studies on non-treated bone from many species have demonstrated that fatigue-
induced micro-damage accumulation compromises mechanical integrity.[31–35] Further, in
a well-controlled dog model, increases in the average length of micro-cracks with
bisphosphonate treatment versus saline control were evident within cortical bone after three
years.[8, 17] This aspect of micro-damage, and no other, including the density of cracks
(#/mm2), has been found altered in cortical bone of dog rib only with bisphosphonate
treatment.
The current study evaluated the cyclic fatigue behavior of cortical bone from dogs that had
been treated for three years with two clinically relevant doses of oral alendronate. A
conventional engineering fatigue-life approach was utilized to determine whether the
number of cycles to failure is a function of alendronate treatment. The hypotheses tested
were that long-term bisphosphonate treatment impairs the fatigue-life and tissue-level
properties of cortical bone, and does so in a dose-dependent manner. Observations were also
made of trabecular and cortical tissue micro-architecture, the osteons and embedded cell
lacunae.
2 Materials and Methods
2.1 Animal Model
36 adult female beagles (1–2 years old) were purchased from LBL (Reelsville, IN). On
arrival, lateral thoracic x-rays of all dogs were obtained under anesthesia (Pentothal, 10
mg/kg, intravenous, Abbott Laboratories, Chicago, IL), to confirm skeletal maturity (closed
proximal tibia and lumbar vertebral growth plates). Animals were housed 2 per cage in
environmentally controlled rooms and fed standard dog chow containing 1.2% calcium,
1.0% phosphorus, and 850 IU/kg vitamin D3 (Diamond Premium Adult, Diamond Pet
Foods, Meta, MO). Water was available at all times. After 2 weeks of acclimatization, dogs
were assigned to the 3 equal-sized treatment groups based on matched body masses. Groups
were treated daily with an oral dose of vehicle (VEH, 1mL/kg saline) or Alendronate (ALN,
0.2 mg/kg or 1.0 mg/kg; Merck) for 3 years.[8] Alendronate was dissolved in saline as either
a 0.05% solution (0.2 mg dose) or a 0.2% solution (1.0 mg dose) with a correction for the
16.4% moisture content. Alendronate doses were chosen to correspond to doses used
clinically for the treatment of postmenopausal osteoporosis and Paget’s disease,
respectively. Appropriate amounts of the alendronate solution were supplemented with
saline to reach a total volume of 10 mL for each daily dose. Doses were administered with a
syringe each morning after an overnight fast and at least 2 hours before feeding. No dogs
were lost prior to euthanasia and all appeared healthy. Animals were euthanized by
intravenous administration of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special).
After death, right 10th and 11th ribs were excised and stored frozen (−20°C) in saline soaked
gauze. All procedures were approved by the Indiana University School of Medicine Animal
Care and Use Committee. Each measurement was made by one observer blinded to
treatments received in each group.
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2.2 Biomechanical Fatigue Testing
Data for bones from these dogs have been presented previously.[8, 13] However, data
presented here are for cyclically loaded rib bone. This bone was fresh frozen immediately
after euthanasia and was stored for two years prior to machining for testing. Beams were
prepared from medial and lateral 11th rib cortices using slicing equipment (Buehler Isomet
5000, Barranca Diamond-303 Professional 102 mm × 360 µm diamond-coated lapidary
blade). A slow speed (2500 rpm, 3.0 mm/min feed rate) was used to minimize machining
marks and no additional polishing was done. First, each rib was cut into 4 approximately
equal length sections (Figure 1a). These sections were potted in quick setting resin cement
(Bondo) and a 1.5 mm primary section was made along the medio-lateral axis. Secondary
sections were introduced in the medial and lateral cortex to obtain beams of rectangular
cross-sectional geometry (1.5 mm × 0.5 mm) and 10–12 mm length (Figure 1b). In this
configuration, the long-axis of osteons is oriented parallel to the beam length. The uniform
rectangular geometry was maintained equivalent for each beam (VEH: 1.57±0.11 mm ×
0.48±0.04 mm; ALN0.2: 1.51±0.05 mm × 0.50±0.05 mm; ALN1.0: 1.54±0.10 mm ×
0.52±0.06 mm). The strict geometrical adherence forced the number of beams prepared from
each rib to vary due to bone curvature. A total of 92 beams were prepared (1–5 beams per
rib).
For mechanical testing, beams were centered in a 4-point loading fixture with the periosteal
side in tension and the endosteal side in compression. The outer and inner supports were set
6 mm and 2 mm apart, respectively. All tests were conducted at room temperature in a
controlled lab environment with the specimen submerged in a saline bath (Sigma Buffered
Saline with PO4, MgCl2 and CaCl2, D86622).[32] Cyclic loads were applied sinusoidally at
a stress ratio (R = σmin/σmax) of 0.1 (Figure 1c) and frequency of 2 cycles per second (Hz),
under load control by an electro-mechanical actuator (Bose Testbench). Fatigue loads were
applied with stress amplitudes (σa = ½[σmax − σmin]) ranging from 45–85 MPa.
Beams obtained from the same rib were tested at different stress amplitudes. Thus, fatigue
response at any given stress amplitude was comprised of beams from several ribs. Beams
were tested until failure or a pre-defined number of cycles (N=250,000). Failure was defined
by either fracture of beam or a 2.5 mm total deflection, whichever occurred first. The
rationale for the deflection failure limit was that in our preliminary work, beams that had not
attained catastrophic failure had entered into the tertiary phase of, but were not progressing
toward, failure. The load vs. load-line displacement data was recorded at 100 Hz and was
used to calculate the stress (σ) and strain (ε) according to conventional beam theory. Secant
modulus (E) in a given cycle, defined as the slope of the line connecting the 2 points, σmax,
εmax and σmin, εmin (Figure 1c), was monitored throughout the test and plotted after test
completion at specific fractions of the total fatigue life.[36]
Loss of modulus (ΔE) over the fatigue life was calculated by subtracting the final Ef just
prior to failure (1 cycle) from the initial Ei (during the 10th cycle). All specimens self-
adjusted in the loading fixtures within 10 cycles to achieve the prescribed σa. Fatigue life
was modeled using a power law for both σa and ε so that σa=A(Nf)B and ε =A(Nf)B, where
Nf is the number of cycles to failure, and A and B are coefficient and exponent, respectively.
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All mechanical parameters, including moduli and cycles to failure, were observed to be site
specific with differences of 25 – 50% (p<0.05) between beams machined from different
cortices (Tables S1 and S2). This was ascribed to differences in porosity, where highly
porous beam specimens of the lateral cortex had individual osteonal average canal area
(Ca.Ar) measured by histomorphometry that exceeded the size of any canal found medially
and total Ca.Ar that exceeded 3% of total beam cross-sectional area. The geometrical
constraints of the rib cortices did not allow production of enough lateral beams for a
complete statistical analysis. Therefore, data presented in the main text are from medial
beams with data from no fewer than 2 dogs per group represented at each stress level. Data
from both cortices are reported in supplemental results.
2.3 Histomorphometry
After mechanical testing, beams were bulk stained in 1% basic fuchsin and embedded in
polymethyl-methacrylate using standard staining and embedding protocols.[8, 16, 22, 37]
The plastic blocks were then cut to obtain 300 µm thick sections, transverse to the beam
length. Sections were ground to 100 µm thickness and fine polished with alumina slurries
(successive particle diameters of 1.0 and 0.05 µm) on a cloth wheel (Buehler Isomet). Bone
beam cross sections were imaged under a bright field microscope (Eclipse 50i, Nikon) at
10× magnification and stitched together using a graphics editing program (Adobe Photoshop
CS5). For each bone beam, 3–5 cross sections from the mid-span were imaged. Osteon
cement lines and Haversian canals were traced, and osteocyte lacunae point counted on the
digital images with an interactive pen/tablet desktop workstation (Wacom Cintiq 21UX).
Thus, cross sections were analyzed for micro-architectural parameters, including canal
porosity (average canal area, Ca.Ar; canal density, Ca.Dn), osteonal composition (average
osteon area, On.Ar; osteon density, On.Dn), and osteocyte lacunae density (Ot.Lc.Dn) in
each of the three compartments, osteonal, interstitial and combined total beam cross-
sectional area.[38]
2.4 µCT
Randomly selected 10th ribs (n=6/group) were evaluated by micro-computed tomography
(SkyScan 1172 µCT; 80keV, 126µA) for density and morphology. Ribs were submerged in
saline and scanned, two at a time, at an isotropic voxel resolution of 17 µm. Density
calibration phantoms (0.25 and 0.75 g/cm3) were also scanned to enable cortical (Ct) tissue
mineral density calculations (TMD). Cortical and trabecular traits were measured in an 8
mm length of the midspan of each rib [average cortical width (Ct.Wi), cortical bone area
(Ct.Ar), medullary (or marrow) area (Ma.Ar) and Ct.Ar normalized by total area within the
periosteal envelope (Ct.Ar/Tt.Ar); trabecular thickness (Tb.Th), separation (Tb.Sp), number
(Tb.N), pattern factor (Tb.Pf), area (Tb.Ar) and bone mineral density (Tb.BMD)].
2.5 Analysis of Data
To investigate variance between treatment groups, most data sets were analyzed using
analysis of variance (ANOVA). Analysis of covariance (ANCOVA) was utilized to assess
differences between groups in fatigue life and examine possible relationships between
Ot.Lc.Dn and Ei. Post-hoc analysis was completed with Tukey HSD for multiple
comparisons (Matlab Statistics Toolbox). Normality of data sets was determined with
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Shapiro-Wilk's Test.[39] Statistical significance is reported at p<0.05, unless otherwise
noted.
3 Results
3.1 Mineral Density and Structure from Whole Ribs
ALN treatment did not affect rib Ct.TMD (Table 1) based on X-ray absorption as measured
by µCT. Cortical bone structure reflected effects of modified resorption in that the average
cross-sectional Ct.Ar/Tt.Ar was significantly (p<0.05) greater with drug treatment versus
VEH (ALN0.2: +9%; ALN1.0: +13%). This was attributed to greater amounts of bone at the
endosteal surfaces as evidenced by significantly (p<0.05) smaller Ma.Ar compared to VEH
(ALN0.2: – 20%; ALN1.0: −25%). The average cross-sectional area fraction occupied by
trabecular bone (Tb.Ar/Ma.Ar) was also significantly (p<0.05) greater with ALN1.0 (+34%)
versus VEH treatment (Table S3). This was attributed to a significant (p<0.05) decrease
(−34%) in the average separation (Tb.Sp) between the plate-like trabeculae.
3.2 Biomechanical Fatigue Testing
Cyclic mechanical loads imposed on cortical bone beams exposed differences in mechanical
properties of treated tissues. Modulus loss was observed as cycle number increased and
exhibited the typical 3-phase response in all specimens (Figure S1). Average modulus of the
initial loading cycle, Ei, and just prior to the final loading cycle, Ef, were significantly lower
for ALN1.0 treatment compared to VEH by 21% (p<0.001) and 30% (p<0.01), respectively
(Figure 2a). Ei was also significantly lower for ALN1.0 compared to ALN0.2 by 15%
(p<0.01). No significant differences were found for Ei or Ef between ALN0.2 and VEH
(p>0.16), Ef between ALN1.0 and ALN0.2 (p>0.80), or ΔE between any treatment group
(p>0.25). ALN treatment resulted in a reduction of the fatigue life of cortical bone (Figure 3)
as the σa power-law fit for the ALN1.0 group revealed that these bones took 3-fold fewer
cycles to fail compared to those from VEH (p<0.05). No significant differences were found
between ALN0.2 and either ALN1.0 or VEH, though a trend for dose effects was indicated
by ANCOVA (p<0.01). While a significant p-value was indicated for the effect of cycles on
apparent strain (ε) amplitude, the Tukey HSD on the power-law fit models did not reach
significance (p>0.14) for any difference between groups (Figure 3).
3. 3 Cortical Micro-architecture
The micro-architecture of cortical osteonal bone consists of 3 main features: osteons,
osteonal canals and the interstitial space between the osteons. Morphometry of stained
histological cross sections revealed that osteonal area in beams from the ALN1.0 treated
group was significantly (p<0.01) smaller than VEH (Figure 4a,b). Since the density of
osteons did not differ between treatments, the average osteon area was 14% smaller (p<0.01)
for ALN1.0 compared to VEH. No differences (p>0.15) were observed between ALN0.2
and the other groups in osteon area. Osteonal canal size was not different (p>0.15) between
any of the 3 groups, with all groups exhibiting average Ca.Ar below 2.5% (Table 2).
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3.4 Osteocyte Lacunae Density
The cell population in cortical bone tissue is predominantly composed of osteocytes, each
one positioned within a single lacuna in the osteonal or interstitial areas. Morphometry of
the cortical beam cross sections revealed that osteocyte lacunae density (Ot.Lc.Dn) within
osteons from both the ALN0.2 (p<0.01) and ALN1.0 (p<0.05) treated groups was at least
20% lower than in VEH (Figure 4c). Ot.Lc.Dn of the interstitial spaces was not significantly
different than that within osteons for each group and was similarly lower for drug-treated
groups (ALN0.2: 1059±273; ALN1.0: 1141±378, vs. VEH: 1343±301). Thus, the overall
total Ot.Lc.Dn followed the same trend of 20% reduction (p<0.05) for ALN versus VEH-
treated bone. Examination of the relationships between mechanical properties and Ot.Lc.Dn
revealed that a moderately strong correlation (R=0.54) existed such that greater Ei implied
greater Ot.Lc.Dn when data from the groups were pooled together. No differences between
groups were found in the linear regression models (Figure 5).
4 Discussion
Long-term (3-year) treatment with high-dose ALN has adverse effects on the mechanical
behavior of cyclically loaded cortical bone tissue. These new findings have implications for
atypical fracture risk and occurred despite the benefit that this drug has for trabecular micro-
architecture in highly remodeled areas of the skeleton, as was reinforced in the current
study.[2, 14, 18] Not surprisingly, the trabecular data for ALN-treated, aging female beagles
(Table S3) reflect that clinical use of bisphosphonates maintains bone in trabecular regions
and reduces fracture risk.[1, 3–7] Conversely, the long-term effects of bisphosphonates on
cortical bone have recently come under greater scrutiny by the research community and the
FDA due to reports of rare but serious types of atypical fracture.[1, 23–30] Though the
mechanisms require further elucidation, one distinct difference with bisphosphonate versus
vehicle treatment in the dog model is greater length of micro-cracks in cortical bone.[8, 17]
This may be indicative of incomplete removal of damage in high-dose treatment that
contributes to the reduced mechanical properties as determined in this study.
Both bone tissue damage and the osteonal bone remodeling that removes damage are
important to bone tissue quality. The damage process dissipates energy during daily cyclic
loading events.[40] From an engineering point of view, repair must keep pace with damage
growth in order to leave the structure intact as appears to be the case for low-dose treatment
in this beagle model. However, greater damage in the form of 25% longer micro-crack
length demonstrated after both 1 and 3 years on the high-dose ALN suggested a reduction in
tissue-level toughness, or the amount of energy required to fracture whole ribs under simple,
mono-tonic, quasi-static mechanical loading.[8, 17] Because bone structure is preserved or
even enhanced with ALN treatment as confirmed in the present study for both low and high
doses compared to VEH (Table 1), the apparent-level tissue toughness was previously
estimated from whole-bone tests. Elucidating the possible mechanisms behind this estimated
loss in toughness helped motivate the current study, and separating the effects from those
due to whole-bone geometry required machining prismatic beams. Furthermore, the quasi-
static loading used previously did not allow for the study of damage processes within the
tissue as relatively little time is available for the development of damage, i.e., quasi-static
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mechanical tests to failure typically take no more than minutes to complete, while many of
the cyclic fatigue tests completed for this study took longer than a day.
More completely capturing one aspect of the complex nature of in vivo cyclic mechanical
loading by performing fatigue bending has revealed a possible mechanical mechanism
behind the weakening and atypical fracture of cortical bone tissue with long-term
bisphosphonate treatment. Proposed contributors to the atypical fracture side-effect of
bisphosphonates are also consequences of reduced remodeling and include increased tissue
age, homogeneity, mineralization and accumulation of non-enzymatic glycation products.[9,
11, 12, 13, 19, 40] These may all contribute to the tissue-level mechanical properties
previously found. For example, nanoindentation for hardness demonstrated increased tissue
modulus in trabeculae of iliac crest biopsies of patients with lower bone turnover due to
bisphosphonate treatment.[10, 41] No difference was found in the biopsy cortical shell. This
may seem to contradict what was found in the current study, lower Ei with ALN treatment.
However, the apparent-level bending test performed here, as opposed to the tissue-level
nanoindentation test, is more likely to drive existing damage toward propagation and
accumulation. Thus, the most probable mechanical explanation for the findings of reduced
modulus (E, Figure 2a) and number of cycles to failure (Figure 3) in the current study is
greater micro-crack burden in the form of greater crack length in the high-dose ALN
treatment group.[8] Relatively low Ei in 4-point bending might even occur for a hard, brittle
material with high average E as measured by nanoindentation, for example, when inclusions
such as pores and/or differentially mineralized regions are present.
Large, long-lived adult animals, such as dogs and humans, exhibit micro-damage that is
remodeled away by basic multicellular units (BMUs) that are absent from mice and rats.[42,
43] The resulting osteons have interfaces with the old interstitial bone, the cement lines
(Figure 6), which are tough and resist micro-crack propagation.[44–46] Furthermore, during
the remodeling process each osteon is embedded with multiple networked sensors, the long-
lived osteocytes, capable of detecting damage and relaying remodeling activation signals to
target BMUs to damaged areas when required. The density of osteocytes in an osteon is
greatest at the cement line, which represents the reversal of a BMU from resorption to
formation by osteoblasts, and therefore, the first newly differentiated osteocytes.[47] That
osteocyte density is greatest at an interface, where damage eventually propagates to and
accumulates at, is compatible with the role of osteocytes as damage sensors. The
relationship between osteocyte lacunae density within osteons and Ei (Figure 5) may
indicate impaired detection of damage at the cement line or within the rest of the tissue. This
does not prove that osteocyte density determines mechanical properties at the tissue level.
However, osteocyte deficiency has been associated with osteoporotic fracture and could
contribute to bone fragility through this damage detection mechanism.[48] For example,
reduced osteon size and reduced osteocyte density within osteons may result in a
combination that allows interstitial damage dissociation from an area where normally
detected, the cement line (Figure 6).
While the outer ring represents the oldest tissue of the osteon, much older tissue resides in
the interstitial space on the other side of most cement lines. A consequence of smaller
osteons in the high-dose ALN group (Figure 4a) is that the amount of interstitial cortical
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bone increases (Figure 6). In this older tissue more damage tends to accumulate.[49, 50]
That accumulation has at least two possible explanations. First, the tissue may be more
easily damaged due to biochemical or ultra-structural differences such as greater
accumulation of advanced glycation end-products or higher mineralization.[51, 52] Second,
there may be slower removal and replacement of damaged tissue. At this point only
speculations exist that sites of atypical fracture contain older tissue and that microdamage
accumulates more quickly following a long-term bisphosphonate treatment. Little damage
data has been collected from sites of atypical fracture or from iliac crest biopsies of atypical
fracture patients as was recently reviewed.[53]
Because intracortical BMUs must originate at a blood vessel, generally located in the middle
of an osteon (Figures 4b, 6), removal of interstitial tissue requires either greater activation of
BMUs to place new blood vessels in proximity to the older, damaged tissue or deeper
digging by osteoclasts. Both the activation frequency for new BMUs and the width of
resorption cavities are reduced with ALN in this dog model, yet osteons do turn over and the
density of osteons is not affected (Figure 4a).[8, 14, 17, 51] Based on these measures,
approximately 60% of osteons had their micro-architecture affected over the 3 years of high-
dose ALN treatment, assuming that activation did not occur in the same spatial location
multiple times.[8, 16] The reduction in average osteon cross-sectional size is most likely
attributable to a reduced width (25%) of BMU resorption cavities as measured in trabecular
bone of this dog model with high-dose treatment.[54]
Although we planned and standardized protocols to avoid differences in testing that would
differentially affect the three groups, limitations exist in this study that was designed
primarily to examine the effects on bone tissue mechanical properties after a continuous
term of three-year ALN treatment. First, the time component of fatigue loading allows for
creep to occur, and resulting large deformations could have contributed to the failure of
samples. Greater numbers of beams in the drug-treated groups than control reached our pre-
defined deformation failure criterion (Table S1). Second, a longer duration of dosing might
be expected to result in a greater reduction in number of cycles to failure. This may be
important to determine because the duration of clinical bisphosphonate treatment has been
positively associated with greater atypical fracture risk in the only large, long-term
prospective report to date that included patients out to a maximum of 13 years of drug
treatment.[30] Increased risk of atypical fracture appears to occur at mean and median
bisphosphonate treatment durations of 5 and 7 years in patients.[28, 30] Cortical tissue
replacement periods for dogs of 2+ months are approximately half that for humans, based on
the calculated human remodeling period of 4 – 6 months.[54–56] Thus, the current 3-year
study may be considered time-equivalent to 6 years of treatment in the human and when
effects on fatigue life might be observed. However, whether the differences found in this
study would exist with other durations of treatment or in an established osteoporotic model
is unknown. A third limitation was that bending loads were applied sinusoidally with a
single frequency, and in a single anatomical plane, perpendicular to the long axis of the
osteons (Figure 1b). One of the primary limitations of 4-point bending is that strain (ε) fields
in the nonhomogenous cortical bone tissue beams are likely complex and affected by the
microstructural differences found in the groups. One simplified model for apparent strain (ε)
did not demonstrate differences in fatigue life between the groups (Figure 3). Additionally,
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physiological loads are more complex with multiple modes, directions and time components.
Finally, only rib bone from the beagle was examined. The choice of rib bone versus another
load-bearing bone was made to capture any effects on remodeling. While cortical rib bone of
dogs and humans is not associated with weight bearing, this site undergoes greater
remodeling compared to other bones due to the high frequency of loading associated with
breathing. At a typical breathing rate of 30 breaths per minute (0.5 Hz) the numbers of
loading cycles on dog rib tissue reaches similar values in 4× the length of time of our 2 Hz
dynamic fatigue loading. However, most of those in vivo loading cycles will be at lower
stress levels than we utilized. Because the rib bone is also relatively small, the initial intent
was to include beams cut from both medial and lateral cortices. However, in the course of
the study the lateral cortex was found to have very large osteonal canals (>3% of total beam
area). This large porosity appears to contribute to poor mechanical properties, including a
30% lower initial modulus than in beams from the medial cortex (Table S1).
Despite the limitations, the data provide important clues on the effects of suppressing bone
tissue remodeling. While post-hoc analysis indicated a significantly decreased number of
cycles to failure with high-dose drug treatment only, a trend for dose effects by ANCOVA
(Figure 3, p<0.01) and other interesting data suggest that the low-drug dose also affected
bone tissue quality. While osteon size was not affected by low-dose treatment, the density of
osteocyte lacunae within osteons was significantly lower, in similar fashion to the high-dose
treatment (−20%). If sensor density affects the recruitment of osteoclasts, then loss in
osteocyte density may portend the larger crack lengths measured in this model with high-
dose treatment and loss of mechanical properties. However, whether mechanical differences
at the lower dose would become more apparent with longer duration treatment is unknown.
Results from this study offer insight into the possible link between long-term
bisphosphonate treatment and changes in material properties. While this investigation
showed that high and low-dose ALN successfully maintained cortical tissue mineral density,
results also demonstrate that high-dose ALN treatment reduces stiffness and, most
importantly, fatigue life. During healthy remodeling of cortical tissue, old or damaged bone
is normally replaced with new osteons of similar shape and size, maintaining the overall
osteonal area (Figure 6).[42, 57] The conservation of osteon size not only maintains the
amount of interstitial area where damage tends to be found, but also ensures that osteons
remain in close proximity to one another, providing structural reinforcement. However, this
study has demonstrated that high-dose ALN treatment results in a nearly 14% reduction in
osteonal area, while conserving the total number of osteons. In addition, osteonal
composition is critical for maintaining toughness, as cracks are generally stopped or
deflected by interlamellar debonding inside the osteons, or by delamination at the weak
osteon-matrix interface, i.e., cement line.[41, 43–46] Combined, these results suggest that
the structural components normally contributing to healthy bone tissue are altered by high-
dose ALN treatment and contribute to reduced mechanical properties under cyclic loading
conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ALN alendronate
a amplitude
Ar area
BMU basic multicellular unit
Ca canal
Ct cortical
Dn density
E modulus of elasticity
f final
Hz Hertz
i initial
Lc lacunae
P load
Ma marrow
µCT micro-computed tomography
max maximum
min minimum
N number
Ot osteocyte
On osteon
R ratio
Sp separation
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K stiffness
σ stress
ε strain
TMD tissue mineral density
Tt total
Tb trabecular
VEH vehicle
Wi width
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Figure 1.
Mechanical fatigue testing. (a) Location of cuts for cortical bone beams prepared from 11th
rib highlighted by dotted lines. Outlines show possible locations for primary and final beam
sections made along the medio-lateral axis. (b) Beam specimen geometry and 4-point
bending set-up. Load (P) was directed downward at the top load points. Lines within beam
indicate osteonal orientation. (c) Stress (σa) versus strain (ε) hysteresis for sinusoidal loading
of a single bone beam within a predetermined maximum and minimum stress (inset). Five
representative load cycles out of thousands are plotted. The slope of the line is the modulus
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(E) at the initial (Ni) and final (Nf) full cycles. Ni represents the 10th cycle, and Nf the cycle
just prior to the partial cycle upon which failure occurred.
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Figure 2.
Modulus and modulus loss. (a) Average initial modulus (Ei), final modulus (Ef) and (b)
normalized reduction in modulus (ΔE/Ei = 100% − Ef/Ei). Means ± SD; n = 7 – 10 / group.
Analysis by ANOVA, followed by Tukey HSD. Ei: a vs. ALN0.2 (p<0.01), b vs. VEH
control (p < 0.001). Ef: c vs. VEH (p<0.01).
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Figure 3.
Fatigue-life diagrams for bone beams cyclically tested under 4-point bending at 6 stress
amplitudes (σa). Each point represents the number of cycles to failure (Nf) plotted on a log
scale vs. σa and apparent strain (ε) amplitude for each beam tested at one randomly
predetermined σa. Failure was defined by either fracture of beam or a 2.5 mm total
deflection, whichever occurred first (see 2.2). Medial beams from 2 VEH-treated beagles
had not failed at Nf = 250,000 cycles (indicated by arrows). Each line represents a power
law fit for the mean fatigue response of each treated group with the equations indicated
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(p<0.01 by linear regression). ANCOVA (table insert), followed by Tukey HSD indicated
>3-fold fewer cycles to failure for ALN1.0 versus VEH under the stress amplitudes applied.
No differences exist in models adjusted to apparent strain amplitude.
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Figure 4.
ALN-induced differences in average osteon size and lacunae density. (a) Cross sectional
area contained in osteons normalized by beam area, osteon density (On.Dn) and average
area of osteons (On.Ar) for beams in each of the 3 groups. (b) Section of one beam cross-
section illustrating osteons (large arrow) and osteocyte lacunae (smaller arrows); scale bar =
100 µm. (c) Total and osteon osteocyte lacunae areal density (Ot.Lc.Dn). Means ± SD; n = 7
– 10 / group. ANOVA, followed by Tukey HSD: vs. control (VEH), a p<0.05, b p < 0.01
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Figure 5.
Relationship between initial beam stiffness (Ei) and osteocyte lacunar density (Ot.Lc.Dn). Ei
was moderately and positively correlated with Ot.Lc.Dn for all groups by ANCOVA (table
insert), followed by Tukey HSD (p<0.01). No differences, beyond the previously
demonstrated differences in Ei means, were found (p>0.15).
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Figure 6.
Model for the observations of decreased osteonal size and increased micro-crack length in
long-term ALN-treated cortical bone tissue. Decreases in the resorption width dug by the
osteoclasts of basic multicellular units (BMUs) decrease the average osteon area and total
cement line perimeter, and increase the interstitial area where most micro-cracks initiate and
lengthen. Interstitial (lightest gray) cortical bone is older than osteonal bone. Additionally,
because activation frequency for new BMUs is lower with ALN, the newest of osteons
(darkest gray) may be fewer in number and older on average. The reduced cement line
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perimeter further reduces the tough, energy-absorbing interfaces available for slowing crack
growth and accumulation. These losses in energy-absorbing capacity can lead to a
significant reduction in tissue stiffness and number of cycles to failure as measured in this
study.
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Table 1
Cortical bone traits, as measured by X-ray micro-computed tomography of ribs (n=6/group).
VEH ALN0.2 ALN1.0
Ct.Wi (µm) 470±41 483±45 514±61
Ct.Ar (mm2) 7.43±0.60 7.41±0.77 7.42±0.98
Ma.Ar (mm2) 6.42±0.93 5.14±0.80a 4.84±1.21a
Ct.Ar/Tt.Ar (%) 53.8±3.9 58.7±3.5a 60.8±5.7a
Ct.TMD (g/cm3) 1.16±0.04 1.16±0.03 1.15±0.06
Data represented as mean ± SD were analyzed by ANOVA followed by Tukey HSD: vs. control (VEH)
ap<0.05.
Bone. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Bajaj et al. Page 26
Table 2
Cortical bone osteonal canal area (Ca.Ar) traits, as measured by morphometry of beams.
VEH (n=9) ALN0.2 (n=7) ALN1.0 (n=10)
Ca.Ar (%) 2.02±0.52 2.40±0.50 2.32±0.63
Ca.Ar (µm2) 383±113 500±146 451±171
The first value is normalized by beam cross-sectional area and is equivalent to porosity, and the second is an average for canal size. Data
represented as mean ± SD. No differences by ANOVA comparisons between doses (p>0.15, n.s.).
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